You are here

Article Text

Article menu
Download PDFPDF
DTB select
Prescribing changes following fluoroquinolone safety warning

https://doi.org/10.1136/dtb.2024.000035

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key learning points

    • Fluoroquinolone adverse effects have led to restrictions on their use, label changes and communications to healthcare professionals.

    • Changes in fluoroquinolone prescribing do not appear to correspond temporally to intervention from the medicines regulator.

    • Further work is needed to address fluoroquinolone prescribing practices across several countries.

    Regulatory interventions to restrict fluoroquinolone prescribing in Europe had no consistent or clear temporal effect on prescribing practices in primary care.1

    Overview

    In 2018, the European Medicines Agency (EMA) reported that fluoroquinolone antibiotics were associated with serious, disabling and potentially permanent adverse effects.2 The EMA subsequently issued information to healthcare professionals highlighting the risks. A retrospective population-based cohort study evaluated the impact of the regulatory interventions on prescribing rates of fluoroquinolones across six European countries. The authors …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.